senescence associated long non-coding RNA 3Genealiases: SAL-RNA3 · XLOC_025918
Q-omics provides the consensus-scored SALRNA3 profile across patient tissues and cancer cell-line models. SALRNA3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SALRNA3 is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, SALRNA3 RNA expression shows 6,508 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KICH, and STAD as cancer lineages where SALRNA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SALRNA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SALRNA3 survival associations across molecular data types. SALRNA3 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SALRNA3 RNA expression–survival associations across cancer types. High SALRNA3 expression shows unfavorable associations in UVM, SKCM, KIRC, HNSC, COAD and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for SALRNA3 RNA expression.
This table summarizes SALRNA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SALRNA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SALRNA3 shows lower tumor expression in KICH and higher tumor expression in KIRC. The KICH box plot shows higher SALRNA3 RNA expression in normal versus tumor tissue (log2 FC = −0.041, t-test p = .007).
This table shows molecular features associated with SALRNA3 in patient tissues and cancer cell lines. In patient samples, SALRNA3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
